Evidence map›Paper›PMID 26717806›Full record

ArticleMolecular medicine reports2016

Caveolin-1 is essential in the differentiation of human adipose-derived stem cells into hepatocyte-like cells via an MAPK pathway-dependent mechanism.

Xin Guan, Nan Wang, Fenggong Cui, Yang Liu, Peng Liu, Jingyuan Zhao, Chao Han, Xiaoyan Li, Zhiqian Leng, Ying Li and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Caveolin1: its roles in normal and cancer stem cells.Journal of cancer research and clinical oncology · 2021
    Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Xin GuanRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Nan WangRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Fenggong CuiLiaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development, College of Life Science, Liaoning Normal University, Dalian, Liaoning 116029, P.R. China.
Yang LiuRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Peng LiuRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Jingyuan ZhaoRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Chao HanRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Xiaoyan LiRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Zhiqian LengRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Ying LiRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Xiaofei JiRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Wei ZouLiaoning Key Laboratories of Biotechnology and Molecular Drug Research and Development, College of Life Science, Liaoning Normal University, Dalian, Liaoning 116029, P.R. China.
Jing LiuRegenerative Medicine Centre, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, P.R. China.
Dalian Medical University · CNFirst Affiliated Hospital of Dalian Medical University · CNLiaoning Normal University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adipose-derived stem cells (hADSCs), widely present in the adult human body, are an emerging and attractive tool for the establishment of stem cell-based therapies for the treatment of liver disease. However, the mechanism underlying hADSCs hepatic differentiation remains to be elucidated. Caveolin-1 (Cav-1), a 21-24 kDa membrane structural protein, is important in liver regeneration and development. In the present study, fluorescence immunocytochemistry and western blotting were used to analyze the expression levels of Cav-1 and evaluate its effects on the hepatic differentiation of hADSCs. The results revealed that primary hADSCs preserved the ability to proliferate and differentiate into hepatocyte-like cells. As demonstrated by semiquantitative reverse transcription-polymerase chain reaction, hepatocyte-inducing factors significantly increased the expression of Cav-1 in a time-dependent manner, as indicated by increased expression levels of the albumin (ALB) and α-fetoprotein (AFP) markers. In addition the expression levels of ALB and HNF1A significantly decreased following small interfering RNA-mediated knockdown of Cav-1. The mitogen-activated protein kinase (MAPK) signaling pathway was activated during hepatic differentiation and inhibited following Cav-1 knockdown. These results suggested that Cav-1 may regulate the hepatocyte-like differentiation of hADSCs by modulating mitogen-activated protein kinase kinase/MAPK signaling. The results of the present study will provide experimental and theoretical basis for further clinical studies on stem cell transplantation in the treatment of liver disease.

Indexed as

Cell DifferentiationMAP Kinase Signaling SystemAdipose TissueAdultBiomarkersCaveolin 1Cell SeparationDown-RegulationFemaleHepatocytesHumansMaleMiddle AgedMitogen-Activated Protein Kinase KinasesReproducibility of ResultsStem CellsBiomarkersCaveolin 1Mitogen-Activated Protein Kinase Kinases

Identifiers

PMID26717806
PMCPMC4732856
OpenAlexW2221073929

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.